Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma

Journal of Clinical Oncology

Volumn 26, Issue 9, 2008, Pages 1459-1464

  Hoang, Jenny K ^a   Hoagland, Luke F ^a   Coleman, R Edward ^a   Coan, April D ^a   Herndon II, James E ^a   Patz Jr , Edward F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; UNIVARIATE ANALYSIS; ANALYSIS OF VARIANCE; LUNG TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; SCINTISCANNING; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 41149178048     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.3628     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006
2. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111:1710-1717, 1997
3. Fujii M, Segawa Y, Matsutomo S, Kimura M: [Long-term survivors of non-small cell lung cancer treated with non-surgical therapeutic modalities]. Gan No Rinsho 36:589-592, 1990
4. Kojima A, Shinkai T, Eguchi K, et al: Analysis of three-year survivors among patients with advanced inoperable non-small cell lung cancer. Jpn J Clin Oncol 21:276-281, 1991
5. Ohashi R, Takahashi K, Miura K, et al: Prognostic factors in patients with inoperable non-small cell lung cancer-an analysis of long-term survival patients. Gan To Kagaku Ryoho 33:1595-1602, 2006
6. Paesmans M, Sculier JP, Libert P, et al: Prognostic factors for survival in advanced non-small-cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients - The European Lung Cancer Working Party. J Clin Oncol 13:1221-1230, 1995
7. Takigawa N, Segawa Y, Okahara M, et al: Prognostic factors for patients with advanced non-small cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 15:67-77, 1996
8. Volm M, Koomagi R: Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival. Br J Cancer 82:1747-1754, 2000
9. Usuda K, Saito Y, Sagawa M, et al: Tumor doubling time and prognostic assessment of patients with primary lung cancer. Cancer 74:2239-2244, 1994
10. Patz EF Jr, Connolly J, Herndon J: Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR Am J Roentgenol 174:769-774, 2000
11. Marom EM, McAdams HP, Erasmus JJ, et al: Staging non-small cell lung cancer with whole-body PET. Radiology 212:803-809, 1999
12. Downey RJ, Akhurst T, Gonen M, et al: Pre-operative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22:3255-3260, 2004
13. Hellwig D, Groschel A, Graeter TP, et al: Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging 33:13-21, 2006
14. Higashi K, Ueda Y, Arisaka Y, et al: 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 43:39-45, 2002
15. Jeong HJ, Min JJ, Park JM, et al: Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 23:865-870, 2002
16. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al: Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 17:3201-3206, 1999
17. Duhaylongsod FG, Lowe VJ, Patz EF Jr, et al: Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 110:130-139, 1995
18. Duhaylongsod FG, Lowe VJ, Patz EF Jr, et al: Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 60:1348-1352, 1995
19. Vesselle H, Freeman JD, Wiens L, et al: Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: New contrary data on prognostic role. Clin Cancer Res 13:3255-3263, 2007
20. Dhital K, Saunders CA, Seed PT, et al: [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 18:425-428, 2000
21. Sasaki R, Komaki R, Macapinlac H, et al: [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23:1136-1143, 2005
22. Cerfolio RJ, Bryant AS, Ohja B, et al: The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 130:151-159, 2005
23. Ahuja V, Coleman RE, Herndon J, et al: The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 83:918-924, 1998
24. Mountain CF: A new international staging system for lung cancer. Chest 89:225S-233S, 1986 (suppl)
25. Stitik FP: The new staging of lung cancer. Radiol Clin North Am 32:635-647, 1994
26. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54:594-606, 1993
27. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005
28. Thomas CRJ WT, Cobos E, Turrisi AT: Lung cancer. Atlanta, GA, American Cancer Society, 2001
29. Pirozynski M: 100 years of lung cancer. Respir Med 100:2073-2084, 2006
30. Smith TA: FDG uptake, tumour characteristics and response to therapy: A review. Nucl Med Commun 19:97-105, 1998
31. Wakelee HA, Bernardo P, Johnson DH, et al: Changes in the natural history of nonsmall cell lung cancer (NSCLC): Comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer 106:2208-2217, 2006
32. Mackillop WJ, Dixon P, Zhou Y, et al: Variations in the management and outcome of non-small cell lung cancer in Ontario. Radiother Oncol 32:106-115, 1994
33. Breathnach OS, Freidlin B, Conley B, et al: Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results. J Clin Oncol 19:1734-1742, 2001
34. Marom EM, Munden RF, Truong MT, et al: Interobserver and intraobserver variability of standardized uptake value measurements in non-small-cell lung cancer. J Thorac Imaging 21:205-212, 2006